The Outlook of China's Pharmaceutical Industry in the Post-Covid-19 Era
毛化, 弗若斯特沙利文咨询公司合伙人
Fred MAO, Partner, Frost & Sullivan
9:15 AM-10:00 AM
主题报告2
Keynote Speech2
生物科技企业上市财税关注重点
IPO Accounting Issues for Biotech and Pharmaceutical Companies
杨淑娟,安永北京主管合伙人&大中华区政府及公共服务事业部主管合伙人
Jane YANG,Beijing Chief Managing Partner and Government&Pulic Service Market Segment Leader of Greater China Assurance Partner,Ernst&Young Hua Ming LLC
10:00 AM-10:45 AM
主题报告3
Keynote Speech3
波动市场下的价值之“锚”——医疗行业资本运作趋势展望
The "anchor" of value in fluctuating market -- Prospect of capital operation trend of medical indust
高元,华泰联合大健康部主管兼业务四部主管,董事总经理
GAO yuan, Managing Director,Head of healthcare department,Huatai United Securities
10:45 AM-11:30 AM
圆桌讨论1
Panel 1
港交所拟引入SPAC机制:机遇与挑战
HKEX is about to Introducing SPAC mechanism: Opportunities and Challenges
Moderator
费凡, 安永大中华区生命科学与医疗健康行业联席主管合伙人,华中地区审计部副主管审计服务主管合伙人
Felix FEI, Ernst & Young ,Health Science and Wellness Sector Co-leader, Greater China,Deputy Assurance Leader, China Central Partner, Assurance
Panelists
毛化, 弗若斯特沙利文咨询公司合伙人
Fred MAO, Partner, Frost & Sullivan
11:30 PM-12:15 PM
圆桌讨论2
Panel 2
北交所上市规则解读
Interpretation of IPO rules of Beijing Stock Exchange
Panelists
诸斌, 安永税务与商务咨询合伙人
Raymond ZHU, Tax & Business Advisory Partner of EY
高元, 华泰联合大健康部主管兼业务四部主管,董事总经理
GAO yuan, Managing Director,Head of healthcare department,Huatai United Securities
毛化, 弗若斯特沙利文咨询公司合伙人
Fred MAO, Partner, Frost & Sullivan
傅扬远, 嘉源律师事务所高级合伙人
FU Yangyuan,Senior partner, JIA YUAN LAW OFFICES, Senior partner